Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch
Jakafi disappointed Incyte once when it failed to prevent severe complications of Covid-19. The JAK inhibitor has fallen short again in another Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
